KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Halozyme Therapeutics (HALO) EBITDA (2016 - 2025)

Historic EBITDA for Halozyme Therapeutics (HALO) over the last 17 years, with Q4 2025 value amounting to -$92.9 million.

  • Halozyme Therapeutics' EBITDA fell 15292.9% to -$92.9 million in Q4 2025 from the same period last year, while for Dec 2025 it was $469.0 million, marking a year-over-year decrease of 1495.43%. This contributed to the annual value of $469.0 million for FY2025, which is 1495.43% down from last year.
  • As of Q4 2025, Halozyme Therapeutics' EBITDA stood at -$92.9 million, which was down 15292.9% from $217.9 million recorded in Q3 2025.
  • In the past 5 years, Halozyme Therapeutics' EBITDA ranged from a high of $217.9 million in Q3 2025 and a low of -$92.9 million during Q4 2025
  • Over the past 5 years, Halozyme Therapeutics' median EBITDA value was $90.7 million (recorded in 2021), while the average stood at $95.1 million.
  • Per our database at Business Quant, Halozyme Therapeutics' EBITDA skyrocketed by 167415.45% in 2021 and then crashed by 15292.9% in 2025.
  • Halozyme Therapeutics' EBITDA (Quarter) stood at $56.5 million in 2021, then soared by 31.8% to $74.5 million in 2022, then soared by 35.6% to $101.0 million in 2023, then surged by 73.7% to $175.5 million in 2024, then tumbled by 152.93% to -$92.9 million in 2025.
  • Its EBITDA was -$92.9 million in Q4 2025, compared to $217.9 million in Q3 2025 and $202.4 million in Q2 2025.